Navigation Links
Samuel J. Sears, Jr. Appointed to BioDelivery Sciences Board of Directors
Date:10/25/2011

RALEIGH, N.C., Oct. 25, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Samuel P. Sears, Jr. has been appointed as an independent director of the Company effective October 21, 2011.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

Mr. Sears has extensive experience in the biopharmaceutical, nutraceutical and biotechnology industries.  Since 2006, Mr. Sears has been a partner at the law firm of Cetrulo and Capone, PC, where he currently serves as managing partner, and from 2000 to 2006, he provided private consulting and legal advisory services to start-up and early stage development companies.  Since 2000, Mr. Sears has served as Director, Chairman of the Audit Committee, Chairman of the Executive Committee, and Member of the Compensation Committee of Commonwealth Biotechnologies, Inc., a research and development support services company.  From 1998 to 2000, Mr. Sears served as Vice Chairman and treasurer of American Prescription Providers, Inc., a specialty pharmacy network offering prescriptions and nutraceuticals to patients with chronic diseases.  From 1994 through May 1998, Mr. Sears was Chief Executive Officer and Chairman of Star Scientific, Inc.  From 1968 to 1993, Mr. Sears was in private law practice.  Mr. Sears is a graduate of Harvard College and Boston College Law School.

"BDSI will greatly benefit from the years of experience that Mr. Sears brings from the biotechnology industry as well as in legal matters," stated Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI.  "We look forward to his addition to our Board of Directors."

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation for the treatment of opioid dependence.  Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron).  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release, the presentation described herein and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publically update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.  


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tens of thousands of buyers including Coles Group, El Corte Ingles, Kingfisher, Sears, The Home Depot and Tesco registered to attend China Sourcing Fairs
2. David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial
3. Autism Spectrum Therapies Co-Founder and Chief Clinical Officer Dr. William Frea Appointed to Board of Directors of Los Angeles Chapter of Autism Speaks
4. Wound Management Technologies Completes Acquisition of Secure eHealth, LLC and Other Assets from VirtualHealth Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
5. VirtualHealth Technologies Completes Sale of Secure eHealth, LLC and Other Assets to Wound Management Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
6. Clive Dix Appointed as Chairman of Crescendo Biologics
7. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
8. Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
9. Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
10. Charles E. Lannon Was Appointed as Vice-Chairman of the Board of Directors at Kinex Pharmaceuticals
11. Michael W. Marine Appointed CEO of Sabin Vaccine Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 According to market ... and Demand Forecast to 2022 - Industry Insights by Slice ... Center and Others)" by P&S Market Research, the global ... 2015, and it is expected to grow at a CAGR ... slice type segment is expected to witness the faster growth, ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
(Date:5/3/2016)... KANSAS CITY, Mo. , May 3, 2016 ... of Kansas Medical Center,s Institute for Advancing Medical ... develop and commercialize new drugs, diagnostics and medical ... organizations provides BioNovus Innovations with rights to license, ... "This partnership ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 2016 , ... Nepenthe Laboratory Services (NLS), a premier drug monitoring and toxicology ... food item donations for Food for Lane County, and to help support awareness for ... of the assembly was to create an exciting atmosphere for the kids at Riverbend ...
(Date:5/5/2016)... ... May 05, 2016 , ... BloodHub, ... blood and service orders. Blood suppliers and their hospitals use BloodHub for ... serves 13,000 active users across 2,100 hospitals who use our platform to processes ...
(Date:5/4/2016)... (PRWEB) , ... May 05, 2016 , ... “Less than ... Jeffers, Little City Executive Director. “As one of ten non-profit organizations to participate and ... Points of Light. The ultimate benefit is that for every $1 we invest in ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... million in grants to identify, fund and implement ideas aimed at improving care ... Medicaid. , “Part of our vision for Trinity Health is to drive ...
(Date:5/4/2016)... Charlotte, NC (PRWEB) , ... May 04, 2016 ... ... platform for sleep wellness and sleep disorder management, today announced it has secured ... World Innovation Lab (WiL) and existing investors. The investment will be used by ...
Breaking Medicine News(10 mins):